Watch TBPH. Know when insiders buy.
One email the day a filing lands. Free.
TBPH
Theravance Biopharma, Inc.
17.04
+0.01 +0.06%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
65
PASS · shorts 65
Insiders, 90 days
−$227K
net selling · 0 buys, 3 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $884.7MP/E 16.9DIV YIELD —FCF YIELD —REV TTM $104.3M +35.1%NET INCOME $53.8M +312.9%NET CASH $219.8M52W 13.57 – 20.74SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $20.7M | −20.9% | — | −$8.3M | −$5.9M | −110.8% | -0.11 | −$7M | — | — | Aug 11 |
| Q1 2026 · Mar 31 | $17.7M | +15.0% | — | −$9.5M | −$4.9M | — | -0.10 | $73.3M | — | — | May 7 |
| Q4 2025 · Dec 31 | $45.9M | +144.7% | — | $20M | $61M | — | 1.15 | −$6.1M | $8K | −$6.1M | Mar 23 |
| Q3 2025 · Sep 30 | $20M | +18.5% | — | −$6.5M | $3.6M | — | 0.07 | −$6.5M | $0 | −$6.5M | Mar 23 |
| Q2 2025 · Jun 30 | $26.2M | +83.7% | — | −$2.7M | $54.8M | — | 1.08 | $208.1M | — | — | Aug 11 |
| Q1 2025 · Mar 31 | $15.4M | +6.1% | — | −$14.4M | −$13.6M | — | -0.27 | $43M | — | — | May 7 |
| Q4 2024 · Dec 31 | $18.8M | +6.8% | — | −$9.2M | −$15.5M | — | -0.31 | −$902K | $190K | −$1.1M | Mar 23 |
| Q3 2024 · Sep 30 | $16.9M | +7.5% | — | −$10.8M | −$12.7M | — | -0.26 | −$5.2M | $15K | −$5.2M | Mar 23 |
| Q2 2024 · Jun 30 | $14.3M | — | — | −$15.7M | −$16.5M | — | -0.34 | −$4.4M | $36K | −$4.5M | Mar 23 |
| Q1 2024 · Mar 31 | $14.5M | — | — | −$11.2M | −$11.7M | — | -0.24 | −$1M | $91K | −$1.1M | Mar 23 |
| Q4 2023 · Dec 31 | $17.6M | — | — | −$6.2M | −$8.5M | — | -0.17 | −$854K | $677K | −$1.5M | Mar 7 |
| Q3 2023 · Sep 30 | $15.7M | — | — | −$8.8M | −$8.9M | — | -0.17 | −$2.5M | $21K | −$2.5M | Mar 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $107.5M | — | −$3.6M | $105.9M | 98.5% | 2.06 | $238.5M | $42K | $238.5M | — | — |
| FY2024 · to Dec 31 | $64.4M | — | −$46.9M | −$56.4M | -87.6% | -1.15 | −$11.5M | $332K | −$11.9M | $445K | — |
| FY2023 · to Dec 31 | $57.4M | — | −$56M | −$55.2M | -96.1% | -1.00 | −$27M | $2.5M | −$29.5M | $197.1M | — |
| FY2022 · to Dec 31 | $51.3M | — | −$92M | $872.1M | 1698.5% | 11.85 | −$187M | $572K | −$187.6M | $128.8M | — |
| FY2021 · to Dec 31 | $55.3M | — | −$257.8M | −$199.4M | -360.6% | -2.87 | −$207.9M | $3.4M | −$211.3M | — | — |
| FY2020 · to Dec 31 | $71.9M | — | −$297.6M | −$278M | -386.9% | -4.46 | −$250.4M | $6.6M | −$257M | — | — |
Every number comes from Theravance Biopharma, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.